FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078953847> ?p ?o ?g. }

• W2078953847 abstract "Retigabine (international nonproprietary name)/ezogabine (United States adopted name) is an antiepileptic drug (AED) that enhances KCNQ (Kv7) potassium channel activity.The aim of this study was to explore the relationship between retigabine/ezogabine systemic exposure and efficacy and adverse events (AEs) of retigabine/ezogabine from Phase III clinical trials.Data were combined from Studies 301 and 302, which were both randomized, double-blind, placebo-controlled, multicenter, parallel-group studies with similar inclusion and exclusion criteria. All patients had partial-onset seizures and were receiving 1 to 3 concomitant AEDs. Systemic exposure was predicted for each patient as the average steady-state AUC0-τ during the 12-week maintenance phase, based on a population pharmacokinetic model developed for retigabine/ezogabine. Efficacy end points included reduction in total partial-seizure frequency from baseline and probability of ≥50% reduction from baseline in seizure frequency. The probabilities of occurrence of 6 AEs were also evaluated.AUC0-τ values increased linearly over the 600- to 1200-mg/d dose range. Over the entire AUC0-τ range, the probability of efficacy was greater than that for any AE. The slopes of the exposure-response relationship for probability of dizziness and abnormal coordination were similar to that for efficacy, whereas the slopes for dysarthria, somnolence, tremor, and blurred vision were shallower, indicating that the probability of these events occurring was less affected than the probability of efficacy by increases in retigabine/ezogabine AUC0-τ.Based on the summary statistics of pharmacokinetic parameters, systemic exposure to retigabine/ezogabine increased linearly with dose (600-1200 mg/d). Population pharmacokinetics and pharmacodynamics showed that the probability of efficacy and AEs increased with increasing systemic retigabine/ezogabine exposure, and the probability of efficacy was higher than the probability of any of the AEs. The 35%-50% between-patient variability and overlap between retigabine/ezogabine dose levels in AUC0-τ values indicate that, as with other AEDs, doses should be individually titrated based on a balance between efficacy and tolerability." @default.
• W2078953847 created "2016-06-24" @default.
• W2078953847 creator A5042973942 @default.
• W2078953847 creator A5062493243 @default.
• W2078953847 creator A5084360444 @default.
• W2078953847 creator A5091057786 @default.
• W2078953847 date "2013-08-01" @default.
• W2078953847 modified "2023-09-27" @default.
• W2078953847 title "Efficacy and Tolerability Exposure–Response Relationship of Retigabine (Ezogabine) Immediate-Release Tablets in Patients With Partial-Onset Seizures" @default.
• W2078953847 cites W1892342982 @default.
• W2078953847 cites W1969680395 @default.
• W2078953847 cites W1985901897 @default.
• W2078953847 cites W1987357626 @default.
• W2078953847 cites W1993615180 @default.
• W2078953847 cites W1999099291 @default.
• W2078953847 cites W2005134750 @default.
• W2078953847 cites W2013844266 @default.
• W2078953847 cites W2013858720 @default.
• W2078953847 cites W2020794407 @default.
• W2078953847 cites W2021854043 @default.
• W2078953847 cites W2023459069 @default.
• W2078953847 cites W2024627319 @default.
• W2078953847 cites W2033494215 @default.
• W2078953847 cites W2042515922 @default.
• W2078953847 cites W2055127006 @default.
• W2078953847 cites W2055766784 @default.
• W2078953847 cites W2068942851 @default.
• W2078953847 cites W2070013574 @default.
• W2078953847 cites W2071032731 @default.
• W2078953847 cites W2071644822 @default.
• W2078953847 cites W2072002678 @default.
• W2078953847 cites W2094019929 @default.
• W2078953847 cites W2097238122 @default.
• W2078953847 cites W2121382073 @default.
• W2078953847 cites W2124725518 @default.
• W2078953847 cites W2126928912 @default.
• W2078953847 cites W2137263523 @default.
• W2078953847 cites W2138758167 @default.
• W2078953847 cites W2148662056 @default.
• W2078953847 cites W2164439848 @default.
• W2078953847 cites W2165094762 @default.
• W2078953847 cites W2166707375 @default.
• W2078953847 cites W2168858520 @default.
• W2078953847 cites W2318319321 @default.
• W2078953847 doi "https://doi.org/10.1016/j.clinthera.2013.06.012" @default.
• W2078953847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23916044" @default.
• W2078953847 hasPublicationYear "2013" @default.
• W2078953847 type Work @default.
• W2078953847 sameAs 2078953847 @default.
• W2078953847 citedByCount "10" @default.
• W2078953847 countsByYear W20789538472014 @default.
• W2078953847 countsByYear W20789538472015 @default.
• W2078953847 countsByYear W20789538472016 @default.
• W2078953847 countsByYear W20789538472020 @default.
• W2078953847 countsByYear W20789538472022 @default.
• W2078953847 crossrefType "journal-article" @default.
• W2078953847 hasAuthorship W2078953847A5042973942 @default.
• W2078953847 hasAuthorship W2078953847A5062493243 @default.
• W2078953847 hasAuthorship W2078953847A5084360444 @default.
• W2078953847 hasAuthorship W2078953847A5091057786 @default.
• W2078953847 hasConcept C112705442 @default.
• W2078953847 hasConcept C126322002 @default.
• W2078953847 hasConcept C142724271 @default.
• W2078953847 hasConcept C197934379 @default.
• W2078953847 hasConcept C204787440 @default.
• W2078953847 hasConcept C27081682 @default.
• W2078953847 hasConcept C2778375690 @default.
• W2078953847 hasConcept C2779384505 @default.
• W2078953847 hasConcept C2908647359 @default.
• W2078953847 hasConcept C42219234 @default.
• W2078953847 hasConcept C71924100 @default.
• W2078953847 hasConcept C98274493 @default.
• W2078953847 hasConcept C99454951 @default.
• W2078953847 hasConceptScore W2078953847C112705442 @default.
• W2078953847 hasConceptScore W2078953847C126322002 @default.
• W2078953847 hasConceptScore W2078953847C142724271 @default.
• W2078953847 hasConceptScore W2078953847C197934379 @default.
• W2078953847 hasConceptScore W2078953847C204787440 @default.
• W2078953847 hasConceptScore W2078953847C27081682 @default.
• W2078953847 hasConceptScore W2078953847C2778375690 @default.
• W2078953847 hasConceptScore W2078953847C2779384505 @default.
• W2078953847 hasConceptScore W2078953847C2908647359 @default.
• W2078953847 hasConceptScore W2078953847C42219234 @default.
• W2078953847 hasConceptScore W2078953847C71924100 @default.
• W2078953847 hasConceptScore W2078953847C98274493 @default.
• W2078953847 hasConceptScore W2078953847C99454951 @default.
• W2078953847 hasLocation W20789538471 @default.
• W2078953847 hasLocation W20789538472 @default.
• W2078953847 hasOpenAccess W2078953847 @default.
• W2078953847 hasPrimaryLocation W20789538471 @default.
• W2078953847 hasRelatedWork W1977160484 @default.
• W2078953847 hasRelatedWork W2003042623 @default.
• W2078953847 hasRelatedWork W202460821 @default.
• W2078953847 hasRelatedWork W2030348591 @default.
• W2078953847 hasRelatedWork W2074207917 @default.
• W2078953847 hasRelatedWork W2328878243 @default.
• W2078953847 hasRelatedWork W2329478898 @default.
• W2078953847 hasRelatedWork W2899084033 @default.
• W2078953847 hasRelatedWork W3159937175 @default.
• W2078953847 hasRelatedWork W3207313530 @default.

• next